|Day Low/High||40.30 / 40.67|
|52 Wk Low/High||35.77 / 42.36|
Big pharma is shaping up to be a consolidating category in 2019.
So far 2019 is proving to be a year where things have a habit of working out right.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
The health care sector may a good place to weather this storm. Here is why and how to play it.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Stocks plunged Wednesday afternoon following the Federal Reserve's decision to raise rates by a quarter point.
U.S. stock futures rise Wednesday as investors prep for an announcement from the Federal Reserve on interest rates; Micron tumbles after a weak second-quarter sales forecast; Glaxo and Pfizer combine their consumer health businesses; FedEx slumps after lowering its outlook.
GlaxoSmithKline shares surged to the top of the European market Wednesday after the drugmaker said it would combine its consumer health division with U.S. rival Pfizer's to create a new division with $13 billion in annual sales.
Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.
Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.
Investors are stressing about the economy and the Fed, which has little room to maneuver, Jim Cramer says.
U.S. stocks ended higher Monday after President Trump backed down from threats to impose additional tariffs on Chinese goods for 90 days while the countries work to negotiate a resolution to ongoing trade disputes.
GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug specialists Tesaro for around $5.1 billion.
SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Tesaro, Inc.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognising its...
A split Congress is the best-case scenario for the drug industry, several analysts said.
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELON, EVRI, GSK, ITGR, MRAM, NPO, PLNT, QIWI, RUN, SFM, WIT Downgrades: ALEX, CVM, METC, SBGI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.